These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35079903)

  • 1. Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis.
    Soraya GV; Ulhaq ZS; Shodry S; A'raaf Sirojan Kusuma M; Herawangsa S; Sativa MO; Gustaf A; Faridwazdi DAN; Florentia SW; Raisa N; Bintang AK; Akbar M
    Neurol Sci; 2022 Jun; 43(6):3649-3670. PubMed ID: 35079903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis.
    Yin Y; Liu Y; Xu M; Zhang X; Li C
    Neurol Sci; 2021 Oct; 42(10):4085-4094. PubMed ID: 34346015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
    Michałowska M; Chalimoniuk M; Jówko E; Przybylska I; Langfort J; Toczylowska B; Krygowska-Wajs A; Fiszer U
    Brain Behav; 2020 Mar; 10(3):e01537. PubMed ID: 32022467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.
    Dos Santos EUD; da Silva IIFG; Asano AGC; Asano NMJ; De Mascena Diniz Maia M; de Souza PRE
    Mol Biol Rep; 2020 Nov; 47(11):8997-9004. PubMed ID: 33151475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
    Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
    J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review.
    Dwivedi A; Dwivedi N; Kumar A; Singh VK; Pathak A; Chaurasia RN; Mishra VN; Mohanty S; Joshi D
    J Geriatr Psychiatry Neurol; 2023 Mar; 36(2):98-106. PubMed ID: 35603896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.
    Purcaro C; Vanacore N; Moret F; Di Battista ME; Rubino A; Pierandrei S; Lucarelli M; Meco G; Fattapposta F; Pascale E
    Neurosci Lett; 2019 Jan; 690():83-88. PubMed ID: 30316985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.
    Yan JH; Ge YL; Wang PZ; Li W; Jin H; Zhang JR; Chen J; Wang F; Li D; Mao CJ; Li K; Liu CF
    Neurosci Lett; 2023 Mar; 801():137140. PubMed ID: 36813078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
    Cheshire P; Bertram K; Ling H; O'Sullivan SS; Halliday G; McLean C; Bras J; Foltynie T; Storey E; Williams DR
    Neurodegener Dis; 2014; 13(1):24-8. PubMed ID: 24008922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis.
    Falla M; Di Fonzo A; Hicks AA; Pramstaller PP; Fabbrini G
    Parkinsonism Relat Disord; 2021 Mar; 84():52-60. PubMed ID: 33561612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.
    Kaplan N; Vituri A; Korczyn AD; Cohen OS; Inzelberg R; Yahalom G; Kozlova E; Milgrom R; Laitman Y; Friedman E; Rosset S; Hassin-Baer S
    J Mol Neurosci; 2014 Jun; 53(2):183-8. PubMed ID: 24633632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India.
    Sarkar S; Biswas A; Ansari S; Choudhury S; Banerjee R; Chatterjee S; Dey S; Kumar H
    Neurosci Lett; 2024 Mar; 825():137706. PubMed ID: 38431040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.
    Hao H; Shao M; An J; Chen C; Feng X; Xie S; Gu Z; Chan P;
    Parkinsonism Relat Disord; 2014 Oct; 20(10):1041-5. PubMed ID: 25034874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease.
    Kakinuma S; Beppu M; Sawai S; Nakayama A; Hirano S; Yamanaka Y; Yamamoto T; Masafumi C; Aisihaer X; Aersilan A; Gao Y; Sato K; Sakae I; Ishige T; Nishimura M; Matsushita K; Satoh M; Nomura F; Kuwabara S; Tanaka T
    eNeurologicalSci; 2020 Jun; 19():100239. PubMed ID: 32346620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.
    Kusters CDJ; Paul KC; Guella I; Bronstein JM; Sinsheimer JS; Farrer MJ; Ritz BR
    Parkinsonism Relat Disord; 2018 Feb; 47():39-44. PubMed ID: 29191473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polymorphisms of catechol-O-methyltransferase and monoamine oxidase B genes among Chinese patients with Parkinson's disease].
    Hao H; Shao M; An J; Chen C; Feng X; Xie S; Gu Z; Chen B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Feb; 32(1):1-5. PubMed ID: 25636089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
    Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population.
    Kiyohara C; Miyake Y; Koyanagi M; Fujimoto T; Shirasawa S; Tanaka K; Fukushima W; Sasaki S; Tsuboi Y; Yamada T; Oeda T; Shimada H; Kawamura N; Sakae N; Fukuyama H; Hirota Y; Nagai M;
    BMC Neurol; 2011 Jul; 11():89. PubMed ID: 21781348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.